These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27863007)

  • 21. Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
    Breccia M; Serrao A; Salaroli A; Loglisci G; Zacheo I; Alimena G
    Br J Haematol; 2012 Dec; 159(5):612-3. PubMed ID: 23043319
    [No Abstract]   [Full Text] [Related]  

  • 22. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors.
    Theil KS; Cotta CV
    Cancer Genet; 2014 May; 207(5):171-6. PubMed ID: 25027637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia.
    Akashi K; Mizuno S; Harada M; Kimura N; Kinjyo M; Shibuya T; Shimoda K; Takeshita M; Okamura S; Matsumoto I
    Exp Hematol; 1993 Jun; 21(6):743-8. PubMed ID: 7684698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of near-triploid with t(2;14)(p12;q32) in blast crisis of chronic myeloid leukemia detected by spectral karyotyping (SKY).
    de Oliveira FM; Scrideli CA; Tone LG
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):274-6. PubMed ID: 17414573
    [No Abstract]   [Full Text] [Related]  

  • 27. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
    Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
    Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J; Maisnar V; Beránek M; Chrobák L
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge.
    Nand S; Barton K
    Leuk Lymphoma; 2007 Feb; 48(2):215-6. PubMed ID: 17325875
    [No Abstract]   [Full Text] [Related]  

  • 30. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].
    Carulli G; Marini A; Caracciolo F
    Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathobiology of lymphoid and myeloid blast crisis and management issues.
    Ilaria RL
    Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
    Kuwao F; Takahashi I
    Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
    Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
    Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
    [No Abstract]   [Full Text] [Related]  

  • 34. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
    Kuyama J; Take H
    Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early T cell precursor lymphoid blast crisis of chronic myeloid leukemia - a novel transformation.
    Senapati J; Devasia AJ; Alex AA; George B
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):43-6. PubMed ID: 25497977
    [No Abstract]   [Full Text] [Related]  

  • 36. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
    Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
    Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
    Hornak T; Mayer J; Cicatkova P; Semerad L; Kvetkova A; Klamova H; Faber E; Belohlavkova P; Karas M; Stejskal L; Cmunt E; Cerna O; Srbova D; Zizkova H; Vrablova L; Skoumalova I; Voglova J; Jurkova T; Chrapava M; Jurcek T; Jeziskova I; Jarosova M; Machova Polakova K; Papajik T; Zak P; Jindra P; Zackova D
    Am J Hematol; 2024 Apr; 99(4):763-766. PubMed ID: 38317312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
    Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
    Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
    [No Abstract]   [Full Text] [Related]  

  • 39. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.